Treatment of nephropathy and lipid disorders. Making progress while heeding Molière's warning.
Bloomgarden
Z T
ZT
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000419:Albuminuria; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000453:epidemiology* / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000503:physiopathology*; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers